Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study

Anti-CD20 antibody treatments, such as obinutuzumab, have been associated with infusion-related reactions (IRRs). In the phase 3 iLLUMINATE study of ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab in first-line chronic lymphocytic leukemia/small lymphocytic lymphoma, IRRs were substantially...

Descripción completa

Detalles Bibliográficos
Autores principales: Greil, Richard, Tedeschi, Alessandra, Moreno, Carol, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Gill, Devinder, Gribben, John G., Flinn, Ian W., Wang, Zhengyuan, Cheung, Leo W. K., Nguyen, Aaron N., Zhou, Cathy, Styles, Lori, Demirkan, Fatih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195966/
https://www.ncbi.nlm.nih.gov/pubmed/34018029
http://dx.doi.org/10.1007/s00277-021-04536-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195966/
https://www.ncbi.nlm.nih.gov/pubmed/34018029
http://dx.doi.org/10.1007/s00277-021-04536-6

Ejemplares similares